glp-1 and hot flashes Can Menopause Impact Receptor Agonists? Answering your questions and dispelling

2 Recently, the potential applications of GLP-1 agonists beyond obesity and T2DM has garnered attention, with focus on their anti-inflammatory properties and pleotropic potential

While Basaglar can be prescribed for both type 1 and type 2 diabetes in adults and also in children aged 6+, Ozempic, however, is only approved for type 2 diabetes & isnt an option for people with type 1 diabetes TL;DR Basaglar (insulin glargine) and Ozempic (semaglutide) treat type 2 diabetes through completely different mechanisms Basaglar is a long acting basal insulin injected daily that directly replaces insulin your body lacks while Ozempic is a GLP 1 receptor agonist injected weekly that enhances your bodys natural insulin production Key differences: Ozempic promotes weight loss (10-15%) while Basaglar often causes weight gain Ozempic reduces A1C by 1.4-1.8% vs Basaglars 0.8-1.5%

Practices that have built indication-aware workflows (i.e., clinical context actively drives PA routing and documentation) are positioned to handle that volume

Epub 2017 Apr 27